Nasus Pharma
NSRXNasus Pharma (NSRX) is a publicly traded, clinical-stage biopharmaceutical company based in Israel. The company's primary business focus is the development and commercialization of intranasal rescue treatments for severe allergic and immune reactions. Its approach centers on a proprietary drug delivery platform designed for nasal administration. The company's lead product candidate, FMXIN002, is an intranasal epinephrine spray being developed as a needle-free treatment for Type 1 allergic reactions, including anaphylaxis. This product has completed a Phase I clinical trial. Nasus Pharma is also developing FMXIN007, an intranasal dexamethasone spray intended for the treatment of acute immune-related adverse events, such as those associated with cancer immunotherapy. As a public company listed on the Tel Aviv Stock Exchange under the ticker NSRX, Nasus Pharma operates within the biotech and specialized drug delivery sectors. Its pipeline targets clear therapeutic areas of high medical need, specifically severe allergic emergencies and immune-mediated conditions, through its intranasal delivery technology.
NSRX · Stock Price
Historical price data
About
Nasus Pharma (NSRX) is a publicly traded, clinical-stage biopharmaceutical company based in Israel. The company's primary business focus is the development and commercialization of intranasal rescue treatments for severe allergic and immune reactions. Its approach centers on a proprietary drug delivery platform designed for nasal administration. The company's lead product candidate, FMXIN002, is an intranasal epinephrine spray being developed as a needle-free treatment for Type 1 allergic reactions, including anaphylaxis. This product has completed a Phase I clinical trial. Nasus Pharma is also developing FMXIN007, an intranasal dexamethasone spray intended for the treatment of acute immune-related adverse events, such as those associated with cancer immunotherapy. As a public company listed on the Tel Aviv Stock Exchange under the ticker NSRX, Nasus Pharma operates within the biotech and specialized drug delivery sectors. Its pipeline targets clear therapeutic areas of high medical need, specifically severe allergic emergencies and immune-mediated conditions, through its intranasal delivery technology.